Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: In vitro profiling and in vivo evaluation

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 21, 2009, Pages 6166-6171

  Semple, Graeme ^a   Tran, Thuy Anh ^a   Kramer, Bryan ^a   Hsu, Debbie ^a   Han, Sangdon ^a   Choi, Juyi ^a   Vallar, Pureza ^a   Casper, Martin D ^a   Zou, Ning ^a   Hauser, Erin K ^a   Thomsen, William ^a   Whelan, Kevin ^a   Sengupta, Dipanjan ^a   Morgan, Michael ^a   Sekiguchi, Yoshinori ^b   Kanuma, Kosuke ^b   Chaki, Shigeyuki ^b   Grottick, Andrew J ^a  

^a ARENA PHARMACEUTICALS   (United States)

^b TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

ATC0175; CNS; Food intake; GPCRs; MCH R1; Obesity; PK PD

Indexed keywords

ATC 0175; MELANIN CONCENTRATING HORMONE RECEPTOR 1; PYRIMIDINE ANTAGONIST; SIBUTRAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; BRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG STRUCTURE; FEMALE; FOOD INTAKE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-OBESITY AGENTS; CYCLOHEXYLAMINES; EATING; HUMANS; MALE; PYRIMIDINES; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SOMATOSTATIN; STRUCTURE-ACTIVITY RELATIONSHIP; WEIGHT LOSS;

EID: 71749107372     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.09.003     Document Type: Article

References (27)

1. Kawauchi H., Kawazoe I., Tsubokawa M., Kishida M., and Baker B.I. Nature 305 (1983) 321
2. Bittencourt J.C., Presse F., Arias C., Peto C., Vaughan J., Nahon J.L., Vale W., and Sawchenko P.E. J. Comp. Neurol. 319 (1992) 218
3. Shimada M., Tritos N.A., Lowell B.B., Flier J.S., and Maratos-Flier E. Nature 396 (1998) 670
4. Chen Y., Hu C., Hsu C.-K., Zhang Q., Bi C., Asnicar M., Hsiung H.M., Fox N., Slieker L.J., Yang D.D., Heiman M.L., and Shi Y. Endocrinology 143 (2002) 2469
5. Marsh D.J., Weingarth D.T., Novi D.E., Chen H.Y., Trumbauer M.E., Chen A.S., Guan X.-M., Jiang M.M., Feng Y., Camacho R.E., Shen Z., Frazier E.G., Yu H., Metzger J.M., Kuca S.J., Shearman L.P., Gopal-Truter S., MacNeil D.J., Strack A.M., MacIntyre D.E., Van der Ploeg L.H.T., and Qian S. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 3240
6. Saito Y., Nothacker H.P., Wang Z., Lin S.H., Leslie F., and Civelli O. Nature 400 (1999) 265
7. Shearman L.P., Camacho R.E., Stribling D.S., Zhou D., Bednarek M.A., Hreniuk H.L., Feighner S.D., Tan C.P., Howard A.H., Van der Ploeg L.H.T., MacIntyre D.E., Hickey G.J., and Strack A.M. Eur. J. Pharmacol. 475 (2003) 37
8. Borowsky B., Durkin M.M., Ogozalek K., Marzabadi M.R., DeLeon J., Heurich R., Lichtblau H., Shaposhnik Z., Daniewska I., Blackburn T.P., Branchek T.A., Gerald C., Vaysse P.J., and Forray C. Nat. Med. 8 (2002) 825
9. Takekawa S., Asami A., Ishihara Y., Terauchi J., Kato K., Shimomura Y., Mori M., Murakoshi H., Kato K., Suzuki N., Nishimura O., and Fujino M. Eur. J. Pharmacol. 438 (2002) 129
10. Souers A.J., Gao J., Brune M., Bush E., Wodka D., Vasudevan A., Judd A.S., Mulhern M., Brodjian S., Dayton B., Shapiro R., Hernandez L.E., Marsh K.C., Sham H.L., Collins C.A., and Kym P.R. J. Med. Chem. 48 (2005) 1318
11. McBriar M.D., Guzik H., Xu R., Paruchova J., Li S., Palani A., Clader J.W., Greenlee W.J., Hawes B.E., Kowalski T.J., O'Neill K., Spar B., and Weig B. J. Med. Chem. 48 (2005) 2274
12. Palani A., Shapiro S., McBriar M.D., Clader J.W., Greenlee W.J., Spar B., Kowalski T.J., Farley C., Cook J., van Heek M., Weig B., O'Neill K., Graziano M., and Hawes B. J. Med. Chem. 48 (2005) 4746
13. Kym P.R., Iyengar R., Souers A.J., Lynch J.K., Judd A.S., Gao J., Freeman J., Mulhern M., Zhao G., Vasudevan A., Wodka D., Blackburn C., Brown J., Che J.L., Cullis C., Lai S.J., LaMarche M., Marsilje T., Roses J., Sells T., Geddes B., Govek E., Patane M., Fry D., Dayton B.D., Brodjian S., Falls D., Brune M., Bush E., Shapiro R., Knourek-Segel V., Fey T., McDowell C., Reinhart G.A., Preusser L.C., Marsh K., Hernandez L., Sham H.L., and Collins C.A. J. Med. Chem. 48 (2005) 5888
14. Mashiko S., Ishihara A., Gomori A., Moriya R., Ito M., Iwaasa H., Matsuda M., Feng Y., Shen Z., Marsh D.J., Bednarek M.A., MacNeil D.J., and Kanatani A. Endocrinology 146 (2005) 3080
15. Thomas, L.; Reichl, R.; Mueller, S. G.; Stenkamp, D.; Schindler, M. A novel MCH-1R antagonist reduces body weight in Rhesus monkeys. NAASO meeting, 2005, P2-224.
16. Tran, T.-A; Beeley, N. R. A.; Thomsen, W.; Lin, I.; Sekiguchi, Y. Discovery of MCH-R1 antagonists from GPCR-directed libraries. 228th ACS National Meeting, Philadelphia, PA, USA, August 22-26, 2004, MEDI-051.
17. Kanuma K., Omodera K., Nishiguchi M., Funakoshi T., Chaki S., Semple G., Tran T.-A., Kramer B., Hsu D., Casper M., Thomsen W., Beeley N.R.A., and Sekiguchi Y. Bioorg. Med. Chem. Lett. 15 (2005) 2565
18. Kanuma K., Omodera K., Nishiguchi M., Funakoshi T., Chaki S., Semple G., Tran T.-A., Kramer B., Hsu D., Casper M., Thomsen W., and Sekiguchi Y. Bioorg. Med. Chem. Lett. 15 (2005) 3853
19. Semple, G.; Kramer, B.; Hsu, D.; Casper, M.; Strah-Pleynet, S.; Thomsen, W.; Lin, I. -L.; Beeley, N.; Bjenning, C.; Whelan, K.; Tran, T.-A.; Sekiguchi, Y.; Kanuma, K.; Omodera, K.; Nishiguchi, M.; Funakoshi T.; Chaki, S. Identification and biological activity of a new series of antagonists of hMCH-R1 228th ACS National Meeting, Philadelphia, PA, USA, August 22-26, 2004, MEDI-7.
20. ATC0175: An Orally Active Melanin-Concentrating Hormone Receptor 1 Antagonist for the Potential Treatment of Depression and Anxiety:. Chaki S., Yamaguchi J., Yamada H., Thomsen W., Tran T., Semple G., and Sekiguchi Y. CNS Drug Rev. 11 (2005) 341
21. Bjenning, C.; Thomsen, W.; Whelan, K.; Creehan, K.; Gonzalez, L.; Al-Shamma, H.; Tran, T.; Semple, G.; Funakoshi, T.; Nishiguchi, M.; Shimazaki, T.; Kanuma, K.; Sekiguchi, Y.; Chaki. S. Novel and potent non-peptide antagonists of Melanin-concentrating hormone receptor-1: ATC0065 and ATC0175 reduce appetite and bodyweight in high-fat diet-fed male rats. Society for Neuroscience Meeting, San Diego CA, Oct 22-27, 2004, Abstr. 629.8.
22. 50 of 3.7 nM. Active compounds were identified by their ability to inhibit this Gαq-dependent response, in a concentration-dependent manner.
23. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Rothman R.B., Baumann M.H., Savage J.E., Rauser L., McBride A., Hufeisen S.J., and Roth B.L. Circulation 102 (2000) 2836
24. Discovery of Orally Efficacious Melanin-Concentrating Hormone Receptor-1 Antagonists as Antiobesity Agents. Synthesis, SAR, and Biological Evaluation of Bicyclo[3.1.0]hexyl Ureas. McBriar M.D., Guzik H., Shapiro S., Paruchova J., Xu R., Palani A., Clader J.W., Cox K., Greenlee W.J., Hawes B.E., Kowalski T.J., O'Neill K., Spar B.D., Weig B., Weston D.J., Farley C., and Cook J. J. Med. Chem. 49 (2006) 2294
25. Potent, Selective, and Orally Efficacious Antagonists of Melanin-Concentrating Hormone Receptor 1:. Tavares F.X., Al-Barazanji K.A., Bigham E.C., Bishop M.J., Britt C.S., Carlton D.L., Feldman P.L., Goetz A.S., Grizzle M.K., Guo Y.C., Handlon A.L., Hertzog D.L., Ignar D.M., Lang D.G., Ott R.J., Peat A.J., and Zhou H.-Q. J. Med. Chem. 49 (2006) 7095
26. The study (RenaSci Consultancy Ltd, BioCity Nottingham, Pennyfoot Street, Nottingham, UK) investigated the effect of chronic administration of 4x (and withdrawal) on body weight and food and water intake in female Wistar rats made obese by exposure to a simplified cafeteria diet (high-fat chow, chocolate and peanut granules) for 12 weeks, that is, dietary-induced obesity (DIO). Following the induction of obesity, rats were given deionised water orally for a 7 day baseline period and then dosed orally once daily with vehicle, one of four doses of 4x (1, 5, 10 and 15 mg/kg) or sibutramine (6 mg/kg PO) for up to 28 days.
27. Stock M.J. Int. J. Obesity 21 (1997) S25